Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
Wolff, Fernando MD; Kreitchmman, Regis MD; Fuchs, Sandra C MD, PhD
Postgraduate Program in Medical Sciences, Faculdade de Medicina (Medical School), Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
To the Editor:
Nunes et al1 tested the performance of noninvasive fibrosis markers in patients coinfected with HIV and hepatitis C virus (HCV). This is an important issue, because biopsy has risks, discomforts, and limitations as a diagnostic method.2,3 Although the study shows promising results, we are concerned about the authors' conclusions that “the performance of the evaluated noninvasive markers of liver fibrosis is equivalent in HCV/HIV-coinfected and HCV-infected subjects.” We believe that the authors could not reach this conclusion, because the 97 subjects studied represent only 26% of the original 370 HCV-infected participants of the Hepatitis C, HIV and Related Morbidity CHARM cohort.
There are many reasons to believe that these two groups are distinct. Data comparing characteristics of the subjects submitted to biopsy with those not submitted were not shown. The role of liver biopsy in HIV/HCV-coinfected patients is controversial.4 Some groups argue that liver biopsy should be performed before treatment, and others argue that HIV patients with immunologic status preserved can be treated for HCV without liver biopsy.4 We do not know which belief prevailed in the cohort from which the patients were selected.
Therefore, we believe that the conclusions about the performance of the methods tested by Nunes et al1 still cannot be generalized to the whole HCV/HIV population, because the sample included in the study is not representative of all HCV/HIV-coinfected patients. Conclusions should be restricted to those patients with the immunologic profile shown in Table 1 of the study: patients with regular to good immunologic conditions, a mean CD4 count of 499 cells/μL, and most with an undetectable HIV viral load.
Fernando H. Wolff, MD
Regis Kreitchmman, MD
Sandra C. Fuchs, MD, PhD
Postgraduate Program in Medical Sciences Faculdade de Medicina (Medical School) Universidade Federal do Rio Grande do Sul Porto Alegre, RS, Brazil
© 2006 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at JAIDS Journal of Acquired Immune Deficiency Syndromes.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics